Clinical Trial Update: Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, pharmacokinetics, and antitumor activity of AK104 in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akesobio Australia Pty Ltd | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED